Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence.
Summary
A key element in the diagnosis of non-alcoholic fatty liver disease (NAFLD) is the differentiation of non-alcoholic steatohepatitis (NASH) from non-alcoholic fatty liver (NAFL) and the staging of the liver fibrosis, given that patients with NASH and advanced fibrosis are those at greatest risk of developing hepatic complications and cardiovascular disease. There are still no available non-invasive methods that allow for correct diagnosis and staging of NAFLD. The implementation of Artificial Intelligence (AI) techniques based on artificial neural networks and deep learning systems (Deep Learning System) as a tool for medical diagnoses represents a bona fide technological revolution that introduces an innovative approach to improving health processes.
Description
The objectives of this observational study are the following:
1. To design a predictive model of significant liver disease due to NAFLD, based on clustering or clustering algorithms (AI)
2. To apply and validate this model to classify patients according to the severity of the disease in such a manner as to provide more effective management of these patients from Primary Care to Hospital Care through process and resource optimization
3. To develop a Deep Learning System based on convolutional neuronal networks for automatic recognition of images in a cohort of subjects with digitized liver biopsies, and to undertake pairwise analysis that allows for correct and exact classification of biopsies from subjects with NASH.
Design:
An observational study of the determination and validation of diagnostic predictive models of NAFLD.
The study has four phases:
Phases I and II refer to both unsupervised and supervised artificial intelligence learning to identify clusters and build diagnostic algorithms. They will be carried out on data generated from the ETHON cohort (see below).
Phase III will consist on applying deep learning system technology as a support strategy to stratify liver biopsies in NALFD patients according to their grade of necro-inflammation and stage of fibrosis. Liver biopsies collected in the Spanish registry of NAFLD up to the beginning of the study will be used.
Finally, a phase IV of validation will be performed with data from patients that are going to be registered in the Spanish registry of NAFLD.
Population:
1. - Study cohort (Phases I-III):
A. Subjects from the general population identified in the ETHON (Epidemiological Study of Hepatic Infections) cohort* that has already been created (12,246 subjects between 19-74 years of age) and B. Subjects belonging to the Spanish registry of NAFLD (HEPAmet) (1,800 subjects already collected at the beginning of the study)
*The ETHON cohort was recruited between 2015 and 2017 to study the hepatitis C prevalence in the Spanish general population aged 19-74 years old. Lavin AC, Llerena S, Gomez M, Escudero MD, Rodriguez L, Estebanez LA, Gamez B, Puchades L, Cabezas J, Serra MA, Calleja JL, Crespo J. Prevalence of hepatitis C in the spanish population. The PREVHEP study (ETHON cohort). J Hepatol. 2017;66:S272.
2. - Validation cohort (Phase IV):
Patients diagnosed with NAFLD by hepatic biopsy recruited in the Spanish and European registers from the beginning of the study.
-Inclusion and exclusion criteria:
Inclusion criteria: subjects aged 19-74 belonging to the ETHON cohort or registered in the Hepamet Spanish registry of NAFLD or the European NAFLD registry
Exclusion criteria: subjects that not fulfill the inclusion criteria and those who did not sign informed consent to participate in the ETHON cohort or to be registered in the mentioned registers.
Study Design
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention
This is an observational study.
Status
Not yet recruiting
Source
Instituto de Investigación Marqués de Valdecilla
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT04099147
- ClinicalTrials.gov processed this data on September 25, 2019
Published on BioPortfolio: 2019-09-26T05:42:33-0400
Clinical Trials
This study will look at how different single and combination study treatments will work in adults with non-alcoholic fatty liver disease (NAFLD) who have features of non-alcoholic steatohe...
It is an observational study of non alcoholic fatty liver disease (NAFLD) patients with a calculated sample size of 90. Liver biopsy proved NAFLD patients will be recruited in this study f...
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease
The purpose of this study is to evaluate how the liver receives and uses fats for energy. This will help the investigators further understand the physical and chemical processes responsibl...
Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids
Non alcoholic fatty liver disease (NAFLD) imposes a high and increasing burden on the NHS, yet there is presently no licensed treatment or validated approach to management. NAFLD predispos...
Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)
In Non-alcoholic fatty (NAFLD) liver disease patients, the investigators hypothesized that rifaximin might act on Gram-negative bacteria and IBO thereby inhibiting LPS-mediated proinflamma...
PubMed Articles
Data on outcomes of non-alcoholic fatty liver disease (NAFLD) from South Asia are lacking. We compared mortality, among those with- and without-NAFLD, after 10-years follow-up among urban, adult Sri L...
Lean non-alcoholic fatty liver disease and development of diabetes: A cohort study.
Non-alcoholic fatty liver disease (NAFLD), a condition associated with multiple metabolic abnormalities, is frequently observed in normal weight individuals (lean NAFLD). The metabolic consequences of...
Non-alcoholic fatty liver disease (NAFLD) is one of the major causes of abnormal liver function tests in hepatology practice. However, not all patients with NAFLD have increased aminotransferase level...
Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and has become an important field of biomedical inquiry. We aimed to determine whether European countries have mo...
MiR-33a has emerged as a critical regulator of lipid homeostasis in the liver. Genetic deficiency of miR-33a aggravates liver steatosis in a preclinical model of non-alcoholic fatty liver disease (NAF...
Medical and Biotech [MESH] Definitions
Fatty Liver, Alcoholic
Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.
Liver Diseases, Alcoholic
Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
Observational Study
A work that reports on the results of a clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study).
More From BioPortfolio on "Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence."
Quick Links
Advanced Search |
Login |
Subscribe |
RSS 
BioPortfolio Twitter Channels (200+ Accounts)
LinkedIn